RecruitingNCT05040373
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Patisiran-LNP Pregnancy Surveillance Program
Sponsor
Alnylam Pharmaceuticals
Enrollment
10 participants
Start Date
Aug 1, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Eligibility
Sex: FEMALE
Inclusion Criteria1
- Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05040373
Related Trials
Effects of Resistance Exercises in Hereditary Sensory-Motor Neuropathy (Charcot-Marie-Tooth Disease)
NCT071521972 locations
Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.
NCT059508671 location
A New Cancer Rehabilitation Process for Chemotherapy-Induced Foot Neuropathy Using Orthopedic Devices
NCT069049891 location